Fifth Era Acquisition Corp I Completes $230,000,000 Initial Public Offering
Each Unit Includes One Class A Ordinary Share andOne Share Right to Receive 1/10th of a Class A Ordinary ShareNew York, NY, March 03, 2025 ...
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently
We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...
Initial public offerings scheduled to debut next week
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
BioSpace4d
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Insider Monkey12d
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
On February 3, three insiders purchased a total of around $94.22 million worth of Metsera shares during the company’s initial ...
Times Union17d
Initial public offerings scheduled to debut next week
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. RedCloud - London ...
Hosted on MSN17d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.